Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Dopamine Transporter Imaging Is Associated With Long-Term Outcomes in Parkinson’s Disease</title><author><name sortKey="Ravina, Bernard" sort="Ravina, Bernard" uniqKey="Ravina B" first="Bernard" last="Ravina">Bernard Ravina</name><affiliation><nlm:aff id="A1">Biogen Idec, Cambridge, Massachusetts, USA</nlm:aff></affiliation></author><author><name sortKey="Marek, Kenneth" sort="Marek, Kenneth" uniqKey="Marek K" first="Kenneth" last="Marek">Kenneth Marek</name><affiliation><nlm:aff id="A2">Institute for Neurodegenerative Disorders, New Haven, Connecticut, USA</nlm:aff></affiliation></author><author><name sortKey="Eberly, Shirley" sort="Eberly, Shirley" uniqKey="Eberly S" first="Shirley" last="Eberly">Shirley Eberly</name><affiliation><nlm:aff id="A3">University of Rochester School of Medicine and Dentistry, Rochester, New York, USA</nlm:aff></affiliation></author><author><name sortKey="Oakes, David" sort="Oakes, David" uniqKey="Oakes D" first="David" last="Oakes">David Oakes</name><affiliation><nlm:aff id="A3">University of Rochester School of Medicine and Dentistry, Rochester, New York, USA</nlm:aff></affiliation></author><author><name sortKey="Kurlan, Roger" sort="Kurlan, Roger" uniqKey="Kurlan R" first="Roger" last="Kurlan">Roger Kurlan</name><affiliation><nlm:aff id="A4">Atlantic Neuroscience Institute, Summit, New Jersey, USA</nlm:aff></affiliation></author><author><name sortKey="Ascherio, Alberto" sort="Ascherio, Alberto" uniqKey="Ascherio A" first="Alberto" last="Ascherio">Alberto Ascherio</name><affiliation><nlm:aff id="A5">Massachusetts General Hospital, Boston, Massachusetts, USA</nlm:aff></affiliation></author><author><name sortKey="Beal, Flint" sort="Beal, Flint" uniqKey="Beal F" first="Flint" last="Beal">Flint Beal</name><affiliation><nlm:aff id="A6">Cornell University School of Medicine, New York, New York, USA</nlm:aff></affiliation></author><author><name sortKey="Beck, James" sort="Beck, James" uniqKey="Beck J" first="James" last="Beck">James Beck</name><affiliation><nlm:aff id="A7">The Parkinson’s Disease Foundation, New York, New York, USA</nlm:aff></affiliation></author><author><name sortKey="Flagg, Emily" sort="Flagg, Emily" uniqKey="Flagg E" first="Emily" last="Flagg">Emily Flagg</name><affiliation><nlm:aff id="A1">Biogen Idec, Cambridge, Massachusetts, USA</nlm:aff></affiliation></author><author><name sortKey="Galpern, Wendy R" sort="Galpern, Wendy R" uniqKey="Galpern W" first="Wendy R." last="Galpern">Wendy R. Galpern</name><affiliation><nlm:aff id="A8">The National Institute of Neurological Disorders and Stroke, Bethesda, Maryland, USA</nlm:aff></affiliation></author><author><name sortKey="Harman, Jennifer" sort="Harman, Jennifer" uniqKey="Harman J" first="Jennifer" last="Harman">Jennifer Harman</name><affiliation><nlm:aff id="A3">University of Rochester School of Medicine and Dentistry, Rochester, New York, USA</nlm:aff></affiliation></author><author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name><affiliation><nlm:aff id="A9">The University of Toronto, Toronto, Ontario, Canada</nlm:aff></affiliation></author><author><name sortKey="Schwarzschild, Michael" sort="Schwarzschild, Michael" uniqKey="Schwarzschild M" first="Michael" last="Schwarzschild">Michael Schwarzschild</name><affiliation><nlm:aff id="A5">Massachusetts General Hospital, Boston, Massachusetts, USA</nlm:aff></affiliation></author><author><name sortKey="Tanner, Caroline" sort="Tanner, Caroline" uniqKey="Tanner C" first="Caroline" last="Tanner">Caroline Tanner</name><affiliation><nlm:aff id="A10">The Parkinson’s Institute, Sunnyvale, California, USA</nlm:aff></affiliation></author><author><name sortKey="Shoulson, Ira" sort="Shoulson, Ira" uniqKey="Shoulson I" first="Ira" last="Shoulson">Ira Shoulson</name><affiliation><nlm:aff id="A1">Biogen Idec, Cambridge, Massachusetts, USA</nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">22976926</idno><idno type="pmc">5404810</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5404810</idno><idno type="RBID">PMC:5404810</idno><idno type="doi">10.1002/mds.25157</idno><date when="2012">2012</date><idno type="wicri:Area/Pmc/Corpus">000828</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000828</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Dopamine Transporter Imaging Is Associated With Long-Term Outcomes in Parkinson’s Disease</title><author><name sortKey="Ravina, Bernard" sort="Ravina, Bernard" uniqKey="Ravina B" first="Bernard" last="Ravina">Bernard Ravina</name><affiliation><nlm:aff id="A1">Biogen Idec, Cambridge, Massachusetts, USA</nlm:aff></affiliation></author><author><name sortKey="Marek, Kenneth" sort="Marek, Kenneth" uniqKey="Marek K" first="Kenneth" last="Marek">Kenneth Marek</name><affiliation><nlm:aff id="A2">Institute for Neurodegenerative Disorders, New Haven, Connecticut, USA</nlm:aff></affiliation></author><author><name sortKey="Eberly, Shirley" sort="Eberly, Shirley" uniqKey="Eberly S" first="Shirley" last="Eberly">Shirley Eberly</name><affiliation><nlm:aff id="A3">University of Rochester School of Medicine and Dentistry, Rochester, New York, USA</nlm:aff></affiliation></author><author><name sortKey="Oakes, David" sort="Oakes, David" uniqKey="Oakes D" first="David" last="Oakes">David Oakes</name><affiliation><nlm:aff id="A3">University of Rochester School of Medicine and Dentistry, Rochester, New York, USA</nlm:aff></affiliation></author><author><name sortKey="Kurlan, Roger" sort="Kurlan, Roger" uniqKey="Kurlan R" first="Roger" last="Kurlan">Roger Kurlan</name><affiliation><nlm:aff id="A4">Atlantic Neuroscience Institute, Summit, New Jersey, USA</nlm:aff></affiliation></author><author><name sortKey="Ascherio, Alberto" sort="Ascherio, Alberto" uniqKey="Ascherio A" first="Alberto" last="Ascherio">Alberto Ascherio</name><affiliation><nlm:aff id="A5">Massachusetts General Hospital, Boston, Massachusetts, USA</nlm:aff></affiliation></author><author><name sortKey="Beal, Flint" sort="Beal, Flint" uniqKey="Beal F" first="Flint" last="Beal">Flint Beal</name><affiliation><nlm:aff id="A6">Cornell University School of Medicine, New York, New York, USA</nlm:aff></affiliation></author><author><name sortKey="Beck, James" sort="Beck, James" uniqKey="Beck J" first="James" last="Beck">James Beck</name><affiliation><nlm:aff id="A7">The Parkinson’s Disease Foundation, New York, New York, USA</nlm:aff></affiliation></author><author><name sortKey="Flagg, Emily" sort="Flagg, Emily" uniqKey="Flagg E" first="Emily" last="Flagg">Emily Flagg</name><affiliation><nlm:aff id="A1">Biogen Idec, Cambridge, Massachusetts, USA</nlm:aff></affiliation></author><author><name sortKey="Galpern, Wendy R" sort="Galpern, Wendy R" uniqKey="Galpern W" first="Wendy R." last="Galpern">Wendy R. Galpern</name><affiliation><nlm:aff id="A8">The National Institute of Neurological Disorders and Stroke, Bethesda, Maryland, USA</nlm:aff></affiliation></author><author><name sortKey="Harman, Jennifer" sort="Harman, Jennifer" uniqKey="Harman J" first="Jennifer" last="Harman">Jennifer Harman</name><affiliation><nlm:aff id="A3">University of Rochester School of Medicine and Dentistry, Rochester, New York, USA</nlm:aff></affiliation></author><author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name><affiliation><nlm:aff id="A9">The University of Toronto, Toronto, Ontario, Canada</nlm:aff></affiliation></author><author><name sortKey="Schwarzschild, Michael" sort="Schwarzschild, Michael" uniqKey="Schwarzschild M" first="Michael" last="Schwarzschild">Michael Schwarzschild</name><affiliation><nlm:aff id="A5">Massachusetts General Hospital, Boston, Massachusetts, USA</nlm:aff></affiliation></author><author><name sortKey="Tanner, Caroline" sort="Tanner, Caroline" uniqKey="Tanner C" first="Caroline" last="Tanner">Caroline Tanner</name><affiliation><nlm:aff id="A10">The Parkinson’s Institute, Sunnyvale, California, USA</nlm:aff></affiliation></author><author><name sortKey="Shoulson, Ira" sort="Shoulson, Ira" uniqKey="Shoulson I" first="Ira" last="Shoulson">Ira Shoulson</name><affiliation><nlm:aff id="A1">Biogen Idec, Cambridge, Massachusetts, USA</nlm:aff></affiliation></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><date when="2012">2012</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p id="P1">Dopamine (DA) transporter (DAT) imaging has been studied as a diagnostic tool for degenerative parkinsonism. Our aim was to measure the prognostic value of imaging for motor and nonmotor outcomes in Parkinson’s disease (PD). We prospectively evaluated a Parkinson’s cohort after enrollment in a de novo clinical trial with a battery of motor (UPDRS), cognitive (Montreal Cognitive Assessment), and behavioral measures. DAT imaging with [<sup>123</sup>I][<bold>β</bold>]-CIT and single-photon emission computerized tomography (SPECT) was performed at baseline and after 22 months. In total, 491 (91%) of the 537 subjects had evidence of DA deficiency on their baseline scan, consistent with PD, and were included in the analyses. The cohort was followed for 5.5 (0.8) years, with a mean duration of diagnosis of 6.3 (1.2). Lower striatal binding at baseline was independently associated with higher risk for clinical milestones and measures of disease severity, including motor-related disability, falling and postural instability, cognitive impairment, psychosis, and clinically important depressive symptoms. Subjects in the bottom quartile for striatal binding, compared to the top quartile, had an odds ratio (95% confidence interval) of 3.3 (1.7, 6.7) for cognitive impairment and 12.9 (2.6, 62.4) for psychosis. Change from baseline in imaging after 22 months was also independently associated with motor, cognitive, and behavioral outcomes. DAT imaging with [<sup>123</sup>I][<bold>β</bold>]-CIT and SPECT, shortly after the diagnosis of PD, was independently associated with clinically important long-term motor and nonmotor outcomes. These results should be treated as hypothesis generating and require confirmation.</p></div></front></TEI><pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<pmc-dir>properties manuscript</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-journal-id">8610688</journal-id><journal-id journal-id-type="pubmed-jr-id">5937</journal-id><journal-id journal-id-type="nlm-ta">Mov Disord</journal-id><journal-id journal-id-type="iso-abbrev">Mov. Disord.</journal-id><journal-title-group><journal-title>Movement disorders : official journal of the Movement Disorder Society</journal-title></journal-title-group><issn pub-type="ppub">0885-3185</issn><issn pub-type="epub">1531-8257</issn></journal-meta><article-meta><article-id pub-id-type="pmid">22976926</article-id><article-id pub-id-type="pmc">5404810</article-id><article-id pub-id-type="doi">10.1002/mds.25157</article-id><article-id pub-id-type="manuscript">NIHMS694549</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Dopamine Transporter Imaging Is Associated With Long-Term Outcomes in Parkinson’s Disease</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ravina</surname><given-names>Bernard</given-names></name><degrees>MD, MSCE</degrees><xref ref-type="aff" rid="A1">1</xref><xref rid="FN1" ref-type="author-notes">*</xref></contrib><contrib contrib-type="author"><name><surname>Marek</surname><given-names>Kenneth</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Eberly</surname><given-names>Shirley</given-names></name><degrees>MS</degrees><xref ref-type="aff" rid="A3">3</xref><xref rid="FN2" ref-type="author-notes">†</xref></contrib><contrib contrib-type="author"><name><surname>Oakes</surname><given-names>David</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="A3">3</xref><xref rid="FN2" ref-type="author-notes">†</xref></contrib><contrib contrib-type="author"><name><surname>Kurlan</surname><given-names>Roger</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Ascherio</surname><given-names>Alberto</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="A5">5</xref></contrib><contrib contrib-type="author"><name><surname>Beal</surname><given-names>Flint</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="A6">6</xref></contrib><contrib contrib-type="author"><name><surname>Beck</surname><given-names>James</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="A7">7</xref></contrib><contrib contrib-type="author"><name><surname>Flagg</surname><given-names>Emily</given-names></name><degrees>BA</degrees><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Galpern</surname><given-names>Wendy R.</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="A8">8</xref></contrib><contrib contrib-type="author"><name><surname>Harman</surname><given-names>Jennifer</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Lang</surname><given-names>Anthony E.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="A9">9</xref></contrib><contrib contrib-type="author"><name><surname>Schwarzschild</surname><given-names>Michael</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="A5">5</xref></contrib><contrib contrib-type="author"><name><surname>Tanner</surname><given-names>Caroline</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="A10">10</xref></contrib><contrib contrib-type="author"><name><surname>Shoulson</surname><given-names>Ira</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="A1">1</xref></contrib></contrib-group><aff id="A1"><label>1</label>Biogen Idec, Cambridge, Massachusetts, USA</aff><aff id="A2"><label>2</label>Institute for Neurodegenerative Disorders, New Haven, Connecticut, USA</aff><aff id="A3"><label>3</label>University of Rochester School of Medicine and Dentistry, Rochester, New York, USA</aff><aff id="A4"><label>4</label>Atlantic Neuroscience Institute, Summit, New Jersey, USA</aff><aff id="A5"><label>5</label>Massachusetts General Hospital, Boston, Massachusetts, USA</aff><aff id="A6"><label>6</label>Cornell University School of Medicine, New York, New York, USA</aff><aff id="A7"><label>7</label>The Parkinson’s Disease Foundation, New York, New York, USA</aff><aff id="A8"><label>8</label>The National Institute of Neurological Disorders and Stroke, Bethesda, Maryland, USA</aff><aff id="A9"><label>9</label>The University of Toronto, Toronto, Ontario, Canada</aff><aff id="A10"><label>10</label>The Parkinson’s Institute, Sunnyvale, California, USA</aff><author-notes><corresp id="FN1"><label>*</label><bold>Correspondence to:</bold> Bernard Ravina, Biogen Idec, 14 Cambridge Center, Cambridge, MA 02142, USA ; <email>Bernard.ravina@biogenidec.com</email></corresp><fn id="FN2"><label>†</label><p>Conducted statistical analyses at the University of Rochester.</p></fn></author-notes><pub-date pub-type="nihms-submitted"><day>18</day><month>3</month><year>2017</year></pub-date><pub-date pub-type="epub"><day>13</day><month>9</month><year>2012</year></pub-date><pub-date pub-type="ppub"><day>15</day><month>9</month><year>2012</year></pub-date><pub-date pub-type="pmc-release"><day>25</day><month>4</month><year>2017</year></pub-date><volume>27</volume><issue>11</issue><fpage>1392</fpage><lpage>1397</lpage><pmc-comment>elocation-id from pubmed: 10.1002/mds.25157</pmc-comment>
<abstract><p id="P1">Dopamine (DA) transporter (DAT) imaging has been studied as a diagnostic tool for degenerative parkinsonism. Our aim was to measure the prognostic value of imaging for motor and nonmotor outcomes in Parkinson’s disease (PD). We prospectively evaluated a Parkinson’s cohort after enrollment in a de novo clinical trial with a battery of motor (UPDRS), cognitive (Montreal Cognitive Assessment), and behavioral measures. DAT imaging with [<sup>123</sup>I][<bold>β</bold>]-CIT and single-photon emission computerized tomography (SPECT) was performed at baseline and after 22 months. In total, 491 (91%) of the 537 subjects had evidence of DA deficiency on their baseline scan, consistent with PD, and were included in the analyses. The cohort was followed for 5.5 (0.8) years, with a mean duration of diagnosis of 6.3 (1.2). Lower striatal binding at baseline was independently associated with higher risk for clinical milestones and measures of disease severity, including motor-related disability, falling and postural instability, cognitive impairment, psychosis, and clinically important depressive symptoms. Subjects in the bottom quartile for striatal binding, compared to the top quartile, had an odds ratio (95% confidence interval) of 3.3 (1.7, 6.7) for cognitive impairment and 12.9 (2.6, 62.4) for psychosis. Change from baseline in imaging after 22 months was also independently associated with motor, cognitive, and behavioral outcomes. DAT imaging with [<sup>123</sup>I][<bold>β</bold>]-CIT and SPECT, shortly after the diagnosis of PD, was independently associated with clinically important long-term motor and nonmotor outcomes. These results should be treated as hypothesis generating and require confirmation.</p></abstract><kwd-group><kwd>Parkinson’s disease</kwd><kwd>dopamine transporter</kwd><kwd>imaging</kwd><kwd>prognosis</kwd></kwd-group></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000828 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000828 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé=
|texte=
}}
| This area was generated with Dilib version V0.6.29. |  |